01—Abstract
Summary
Summary of the 8-K filed January 12, 2026. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. (Nasdaq: EXEL) furnished this Form 8-K under Item 2.02 to report preliminary, unaudited financial results for the fiscal year 2025 (ended January 2, 2026), provide fiscal 2026 financial guidance, and deliver a business update.
The company reported approximately $2.123 billiona in preliminary U.S. net product revenues for the cabozantinib franchise in fiscal 2025, with total revenues of approximately $2.320 billion. Fiscal 2026 guidance calls for total revenues of $2.525 billion to $2.625 billion and net product revenues of $2.325 billion to $2.425 billion. The guidance does not reflect any revenue from a potential U.S. launch of zanzalintinib in previously treated metastatic colorectal cancer, which is under FDA review in combination with atezolizumab.
The audit of the fiscal 2025 financial statements is ongoing and could change the figures, and Exelixis plans to report audited results on February 10, 2026. The update outlines 2026 priorities centered on growing CABOMETYX in renal cell carcinoma and neuroendocrine tumors, advancing zanzalintinib through several pivotal trials (STELLAR-303 and STELLAR-304 topline data expected mid-2026), and progressing early-stage pipeline assets. The company also disclosed that it has repurchased $2.16 billionb of common stock since March 2023 and authorized up to an additional $750 million in repurchases before December 31, 2026.
The filing states that the preliminary results have not been audited or reviewed by the independent registered public accounting firm and may differ materially from the audited financial statements. The information is furnished rather than filed for purposes of Section 18 of the Exchange Act.
02—Key points
Key Highlights
- Preliminary fiscal 2025 net product revenues of approximately $2.123 billion and total revenues of approximately $2.320 billion, both unaudited
- Fiscal 2026 guidance: net product revenues of $2.325 billion to $2.425 billion and total revenues of $2.525 billion to $2.625 billion
- Fiscal 2026 guidance includes a 3.0% U.S. wholesale acquisition cost increase for CABOMETYX and COMETRIQ effective January 1, 2026, and excludes potential zanzalintinib CRC launch revenue
- Fiscal 2026 guidance for R&D expenses of $875 million to $925 million and SG&A expenses of $575 million to $625 million, with an effective tax rate of 21% to 23%
- Zanzalintinib with atezolizumab is under FDA review for previously treated metastatic CRC; STELLAR-303 second endpoint (OS in patients without liver metastases) final analysis and STELLAR-304 topline results are both expected mid-2026
- New $750 million stock repurchase program authorized in October 2025, to be executed before December 31, 2026, following $2.16 billion repurchased since March 2023
- Audit is ongoing and audited fiscal 2025 results will be reported February 10, 2026, so figures could change
03—Questions
Frequently Asked Questions
What revenue did Exelixis report for fiscal 2025?
Exelixis preliminarily reported approximately $2.123 billion in U.S. net product revenues for the cabozantinib franchise and approximately $2.320 billion in total revenues for fiscal 2025. These figures are unaudited and subject to change pending the completion of the audit.
What is Exelixis guiding for fiscal 2026?
The company guides to net product revenues of $2.325 billion to $2.425 billion and total revenues of $2.525 billion to $2.625 billion. Guidance does not include any revenue from a potential U.S. approval and launch of zanzalintinib in previously treated metastatic colorectal cancer.
What is the status of zanzalintinib's regulatory review?
The FDA is reviewing Exelixis' New Drug Application for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer. The filing is based on the phase 3 STELLAR-303 trial, which met one of its dual primary endpoints with a statistically significant reduction in the risk of death versus regorafenib in the intention-to-treat population.
What share repurchase activity has Exelixis undertaken?
Since March 2023, Exelixis has repurchased a total of $2.16 billion of common stock, retiring 76.7 million shares at an average price of $28.14 per share through the end of fiscal 2025. In October 2025, the board authorized up to an additional $750 million in repurchases before December 31, 2026, and the company has begun executing under that program. The program may be modified, suspended or discontinued at any time.
When will Exelixis report audited fiscal 2025 results?
Exelixis will report its audited financial results for the fiscal year ended January 2, 2026 on February 10, 2026. The preliminary results are not audited or reviewed by the independent registered public accounting firm and may differ materially from the audited figures.
04—Continue